ALK Gene Mutation (DBCOND0061043)

Identifiers

Synonyms

ALK gene mutation / Anaplastic lymphoma kinase gene mutation

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Atezolizumab	A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.	Programmed cell death 1 ligand 1target Programmed cell death protein 1target
Cemiplimab	A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.	Programmed cell death protein 1target
Durvalumab	An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.	Programmed cell death 1 ligand 1target Programmed cell death protein 1target
Ipilimumab	A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.	Cytotoxic T-lymphocyte protein 4target
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Tremelimumab	An anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab.	Cytotoxic T-lymphocyte protein 4target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04322890	Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation	Alectinib Almonertinib Brigatinib Ceritinib Cisplatin Crizotinib Entrectinib Erlotinib Gefitinib Lorlatinib Osimertinib Pemetrexed Pralsetinib Savolitinib	treatment	2	recruiting
NCT05200481	Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)	Brigatinib Carboplatin Pemetrexed	treatment	2	active_not_recruiting
NCT03049618	Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475	Pembrolizumab SEphB4-HSA	treatment	2	active_not_recruiting
NCT04849273	A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC	Zotizalkib	treatment	1	terminated
NCT06378892	A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib	Lorlatinib	treatment	2	recruiting
NCT05370469	Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies	No drug interventions	supportive_care	Not Available	active_not_recruiting
NCT05266846	Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK	Bevacizumab Cisplatin Pembrolizumab Pemetrexed	treatment	2	recruiting
NCT03042221	Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy	No drug interventions	Not Available	Not Available	recruiting
NCT06234579	Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)	No drug interventions	Not Available	Not Available	recruiting
NCT05534854	Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes	No drug interventions	Not Available	Not Available	recruiting
NCT05713006	Alectinib Pharmacokinetic in Patients With NSCLC	Alectinib	treatment	1 / 2	recruiting
NCT04708639	Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients	Alectinib	Not Available	Not Available	enrolling_by_invitation
NCT01700582	French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings	No drug interventions	Not Available	Not Available	completed
NCT05724004	Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)	No drug interventions	treatment	Not Available	recruiting
NCT03868423	Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers	Brigatinib	treatment	2	withdrawn